Summit Therapeutics has released more Phase III trial data for ivonescimab in non-small cell lung cancer (NSCLC) as it awaits ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...
The US FDA has sought Indian pharma's help for the cancer drug ifosfamide, while India works to fix its own cisplatin and carboplatin shortage. Here's what is driving both.
Onmanorama on MSN
This Kerala tiger is diagnosed with cancer, begins chemotherapy
Human beings can also get this cancer, which can affect multiple organs.
(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA ® (talazoparib), an oral poly ...
The fight against deadly pancreatic cancer took a positive turn this spring with a study finding a new drug can help patients ...
Modern anticancer medications that combine tumor-fighting drugs with proteins that specifically target cancer cells are a ...
The Food and Drug Administration approved a combination treatment by Merck & Co., Pfizer, and Astellas Pharma for a hard-to-treat form of bladder cancer. The agency greenlit Merck's Keytruda and its ...
Sunvozertinib lung cancer treatment hit a milestone as AstraZeneca paid $600M upfront for Zegfrovy, the first oral pill to ...
Aprepitant injections are in a class of medications called antiemetics. They work by blocking the action of neurokinin, a natural substance in the brain that causes nausea and vomiting. Aprepitant ...
In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results